Drug Price Trends for DAPAGLIFLOZIN-METFORMIN ER

Average Pharmacy Cost for DAPAGLIFLOZIN-METFORMIN ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET	66993-0361-60	5.90045	EACH	2025-06-18
DAPAGLIFLOZIN-METFORMIN ER 10-1,000 MG TABLET	66993-0362-30	11.66161	EACH	2025-06-18
DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET	66993-0361-60	5.87453	EACH	2025-05-21
DAPAGLIFLOZIN-METFORMIN ER 10-1,000 MG TABLET	66993-0362-30	11.62559	EACH	2025-05-21
DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET	66993-0361-60	5.85648	EACH	2025-04-23

Market Analysis and Price Projections for Dapagliflozin-Metformin ER

Introduction

Dapagliflozin-metformin extended release (ER) is a fixed-dose combination (FDC) medication widely used for the treatment of type 2 diabetes mellitus (T2DM) and other conditions such as heart failure and chronic kidney disease. This article provides a comprehensive market analysis and price projections for this medication.

Market Size and Growth

The global dapagliflozin market, which includes the FDC product with metformin, is experiencing significant growth. As of 2024, the market size was valued at USD 3.21 billion and is projected to reach USD 5.47 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 6.70% during the forecast period of 2025 to 2032[3].

Key Drivers of Market Growth

Several factors are driving the growth of the dapagliflozin market:

Increasing Prevalence of Diabetes and Related Conditions

The rising prevalence of diabetes, heart failure, and chronic kidney disease globally is a major driver. According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20-79 were living with diabetes in 2021, with this number expected to rise to 643 million by 2030[3].

Efficacy and Clinical Benefits

Dapagliflozin has been shown to be effective in managing glucose levels, reducing cardiovascular risks, and slowing the progression of chronic kidney disease. This efficacy has positioned it as a critical therapeutic agent, particularly in regions with a high burden of these conditions[3].

Market Segmentation

The global dapagliflozin market is segmented based on several criteria:

Indication

• Type 2 Diabetes Mellitus
• Heart Failure (HFrEF)
• Chronic Kidney Disease (CKD)

Dosage Strength

• 5 mg and 10 mg

Application

• Monotherapy and Combination Therapy

Age Group

• Adult and Geriatric

End User

• Hospitals, Specialty Clinics, and Homecare Settings

Distribution Channel

• Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies[3].

Bioequivalence and Safety Profile

Studies have demonstrated the bioequivalence of the dapagliflozin-metformin FDC product compared to the individual component (IC) formulations. A study conducted in healthy Chinese volunteers showed that the FDC and IC formulations had nearly superimposable plasma concentration-time profiles, indicating bioequivalence. Both formulations were well tolerated with no serious adverse events[1][4].

Pricing and Cost Considerations

The cost of dapagliflozin-metformin ER can be a significant barrier to access, particularly in low- and middle-income countries.

Current Pricing

• The cost for a 30-tablet supply of dapagliflozin-metformin (10 mg-1000 mg) oral tablet, extended release, is around $574 in the U.S., depending on the pharmacy[2].

International Pricing

• Prices can vary significantly internationally. For example, the lowest price on PharmacyChecker.com for dapagliflozin-metformin (10mg/1000mg) is $2.27 per tablet for 84 tablets from accredited online pharmacies[5].

Patient Assistance and Copay Programs

While there are no specific patient assistance programs (PAPs) available for this medication, patients can use discount cards and coupons to reduce costs. The Drugs.com Discount Card, for instance, can save up to 80% or more off the cost of prescription medicines[2].

Challenges and Restraints

Despite its clinical benefits, the high cost of dapagliflozin remains a significant restraint in its global market. This financial burden affects patient access, especially in regions with limited healthcare coverage. The availability of generic versions in the future may help reduce costs, but the initial high pricing continues to limit patient access[3].

Regional Comparisons

Pharmacokinetic (PK) parameters of dapagliflozin in different regions have shown some variations, but these differences are not clinically meaningful. Studies have compared PK parameters in Chinese volunteers with those from Brazil, Russia, and the United States, finding slightly to moderately higher PK parameters in the Chinese population[1].

Future Outlook

The market for dapagliflozin-metformin ER is expected to continue growing driven by the increasing prevalence of diabetes and related conditions. However, the high cost and lack of generic alternatives currently limit broader market penetration.

Generic Drug Development

The development of generic versions of dapagliflozin could significantly reduce costs and increase accessibility, particularly in underserved regions. This could be a crucial factor in the future growth and adoption of the medication[3].

Key Takeaways

• The global dapagliflozin market is projected to grow significantly, driven by the increasing prevalence of diabetes and related conditions.
• The bioequivalence of the FDC product with IC formulations has been established, ensuring similar efficacy and safety profiles.
• High costs remain a significant barrier to access, particularly in low- and middle-income countries.
• Future generic drug development could reduce costs and enhance market penetration.

FAQs

What is the primary use of dapagliflozin-metformin ER?

Dapagliflozin-metformin ER is primarily used for the treatment of type 2 diabetes mellitus (T2DM) and also for conditions such as heart failure and chronic kidney disease.

How does the cost of dapagliflozin-metformin ER vary internationally?

The cost of dapagliflozin-metformin ER can vary significantly internationally, with prices in the U.S. being around $574 for a 30-tablet supply, while accredited online pharmacies can offer prices as low as $2.27 per tablet.

Are there any patient assistance programs available for dapagliflozin-metformin ER?

Currently, there are no specific patient assistance programs (PAPs) available for this medication, but patients can use discount cards and coupons to reduce costs.

What are the key drivers of the growth in the dapagliflozin market?

The key drivers include the increasing prevalence of diabetes, heart failure, and chronic kidney disease, as well as the efficacy of dapagliflozin in managing these conditions.

What is the projected market size of the global dapagliflozin market by 2032?

The global dapagliflozin market is projected to reach USD 5.47 billion by 2032, with a CAGR of 6.70% during the forecast period of 2025 to 2032.

Sources

1. Pharmacokinetic Variables of Dapagliflozin/Metformin Extended Release Fixed-Dose Combination Product Versus Individual Component Formulations in Healthy Chinese Volunteers. PubMed.
2. Dapagliflozin/metformin Prices, Coupons, Copay Cards & Patient Assistance. Drugs.com.
3. Global Dapagliflozin Market Size, Share, and Trends Analysis Report. Data Bridge Market Research.
4. An open-label, randomized, crossover study of comparative pharmacokinetics and bioequivalence of Dapagliflozin + Metformin modified release film-coated tablets. AstraZeneca Clinical Trials.
5. Dapagliflozin/Metformin (Xigduo) Prices - U.S. & International. PharmacyChecker.

Last updated: 2024-12-30